Prognostic Value of Quantitative [F]FDG-PET Features in Patients with Metastases from Soft Tissue Sarcoma

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Dec 24

PMID 34943508

Citations 1

Authors

Gijsbert M Kalisvaart

Willem Grootjans

Judith V M G Bovee

Hans Gelderblom

Jos A van der Hage

Michiel A J van de Sande

Floris H P van Velden

Johan L Bloem

Lioe-Fee de Geus-Oei

Affiliations

Soon will be listed here.

Abstract

Background: Prognostic biomarkers are pivotal for adequate treatment decision making. The objective of this study was to determine the added prognostic value of quantitative [F]FDG-PET features in patients with metastases from soft tissue sarcoma (STS).

Methods: Patients with metastases from STS, detected by (re)staging [F]FDG-PET/CT at Leiden University Medical Centre, were retrospectively included. Clinical and histopathological patient characteristics and [F]FDG-PET features (SUVmax, SUVpeak, SUVmean, total lesion glycolysis, and metabolic tumor volume) were analyzed as prognostic factors for overall survival using a Cox proportional hazards model and Kaplan-Meier methods.

Results: A total of 31 patients were included. SUVmax and SUVpeak were significantly predictive for overall survival (OS) in a univariate analysis ( = 0.004 and = 0.006, respectively). Hazard ratios (HRs) were 1.16 per unit increase for SUVmax and 1.20 per unit for SUVpeak. SUVmax and SUVpeak remained significant predictors for overall survival after correction for the two strongest predictive clinical characteristics (number of lesions and performance status) in a multivariate analysis ( = 0.02 for both). Median SUVmax and SUVpeak were 5.7 and 4.9 g/mL, respectively. The estimated mean overall survival in patients with SUVmax > 5.7 g/mL was 14 months; otherwise, it was 39 months ( < 0.001). For patients with SUVpeak > 4.9 g/mL, the estimated mean overall survival was 18 months; otherwise, it was 33 months ( = 0.04).

Conclusions: In this study, SUVmax and SUVpeak were independent prognostic factors for overall survival in patients with metastases from STS. These results warrant further investigation of metabolic imaging with [F]FDG-PET/CT in patients with metastatic STS.

Citing Articles

Editorial on Special Issue "Quantitative PET and SPECT".

van Velden F, de Geus-Oei L Diagnostics (Basel). 2022; 12(8).

PMID: 36010339 PMC: 9407256. DOI: 10.3390/diagnostics12081989.

References

Casali P, Abecassis N, Aro H, Bauer S, Biagini R, Bielack S . Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Suppl 4):iv268-iv269. DOI: 10.1093/annonc/mdy321. View

Charest M, Hickeson M, Lisbona R, Novales-Diaz J, Derbekyan V, Turcotte R . FDG PET/CT imaging in primary osseous and soft tissue sarcomas: a retrospective review of 212 cases. Eur J Nucl Med Mol Imaging. 2009; 36(12):1944-51. DOI: 10.1007/s00259-009-1203-0. View

Singh T, Sharma A, Sharma A, Bakhshi S, Patel C, Pandey A . Utility of 18F-FDG-PET/CT in management and prognostication of treatment naïve late-stage soft tissue sarcomas. Nucl Med Commun. 2021; 42(7):818-825. DOI: 10.1097/MNM.0000000000001401. View

Vlenterie M, Oyen W, Steeghs N, Desar I, Verheijen R, Koenen A . Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. Anticancer Res. 2019; 39(3):1309-1316. DOI: 10.21873/anticanres.13243. View

Chodyla M, Demircioglu A, Schaarschmidt B, Bertram S, Morawitz J, Bauer S . Evaluation of the Predictive Potential of 18F-FDG PET and DWI Data Sets for Relevant Prognostic Parameters of Primary Soft-Tissue Sarcomas. Cancers (Basel). 2021; 13(11). PMC: 8199532. DOI: 10.3390/cancers13112753. View

Callegaro D, Miceli R, Bonvalot S, Ferguson P, Strauss D, Levy A . Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. Lancet Oncol. 2016; 17(5):671-80. DOI: 10.1016/S1470-2045(16)00010-3. View

Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I . UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016; 6:20. PMC: 5109663. DOI: 10.1186/s13569-016-0060-4. View

Baum S, Fruhwald M, Rahbar K, Wessling J, Schober O, Weckesser M . Contribution of PET/CT to prediction of outcome in children and young adults with rhabdomyosarcoma. J Nucl Med. 2011; 52(10):1535-40. DOI: 10.2967/jnumed.110.082511. View

Gronchi A, Miah A, Dei Tos A, Abecassis N, Bajpai J, Bauer S . Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(11):1348-1365. DOI: 10.1016/j.annonc.2021.07.006. View

10.

Lochner J, Menge F, Vassos N, Hohenberger P, Kasper B . Prognosis of Patients with Metastatic Soft Tissue Sarcoma: Advances in Recent Years. Oncol Res Treat. 2020; 43(11):613-619. DOI: 10.1159/000509519. View

11.

Macpherson R, Pratap S, Tyrrell H, Khonsari M, Wilson S, Gibbons M . Retrospective audit of 957 consecutive F-FDG PET-CT scans compared to CT and MRI in 493 patients with different histological subtypes of bone and soft tissue sarcoma. Clin Sarcoma Res. 2018; 8:9. PMC: 6086048. DOI: 10.1186/s13569-018-0095-9. View

12.

Lee J, Heo E, Moon S, Lee H, Cheon G, Lee M . Prognostic value of total lesion glycolysis on preoperative F-FDG PET/CT in patients with uterine carcinosarcoma. Eur Radiol. 2016; 26(11):4148-4154. DOI: 10.1007/s00330-016-4264-z. View

13.

Chang K, Lim I, Park J, Jo A, Kong C, Song W . The Role of (18)F-FDG PET/CT as a Prognostic Factor in Patients with Synovial Sarcoma. Nucl Med Mol Imaging. 2015; 49(1):33-41. PMC: 4354794. DOI: 10.1007/s13139-014-0301-5. View

14.

Reyes Marles R, Navarro Fernandez J, Puertas Garcia-Sandoval J, Medina F, Mohamed Salem L, Frutos Esteban L . Clinical value of baseline F-FDG PET/CT in soft tissue sarcomas. Eur J Hybrid Imaging. 2021; 5(1):16. PMC: 8413431. DOI: 10.1186/s41824-021-00110-5. View

15.

Van Glabbeke M, Van Oosterom A, Oosterhuis J, Mouridsen H, Crowther D, Somers R . Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and.... J Clin Oncol. 1999; 17(1):150-7. DOI: 10.1200/JCO.1999.17.1.150. View

16.

Frings V, van Velden F, Velasquez L, Hayes W, van de Ven P, Hoekstra O . Repeatability of metabolically active tumor volume measurements with FDG PET/CT in advanced gastrointestinal malignancies: a multicenter study. Radiology. 2014; 273(2):539-48. DOI: 10.1148/radiol.14132807. View

17.

Rueten-Budde A, van Praag V, van de Sande M, Fiocco M . Dynamic prediction of overall survival for patients with high-grade extremity soft tissue sarcoma. Surg Oncol. 2018; 27(4):695-701. DOI: 10.1016/j.suronc.2018.09.003. View

18.

Italiano A, Mathoulin-Pelissier S, Cesne A, Terrier P, Bonvalot S, Collin F . Trends in survival for patients with metastatic soft-tissue sarcoma. Cancer. 2010; 117(5):1049-54. DOI: 10.1002/cncr.25538. View

19.

Billingsley K, Lewis J, Leung D, Casper E, Woodruff J, Brennan M . Multifactorial analysis of the survival of patients with distant metastasis arising from primary extremity sarcoma. Cancer. 1999; 85(2):389-95. View

20.

Chodyla M, Demircioglu A, Schaarschmidt B, Bertram S, Bruckmann N, Haferkamp J . Evaluation of F-FDG PET and DWI Datasets for Predicting Therapy Response of Soft-Tissue Sarcomas Under Neoadjuvant Isolated Limb Perfusion. J Nucl Med. 2020; 62(3):348-353. DOI: 10.2967/jnumed.120.248260. View